177 related articles for article (PubMed ID: 38270826)
21. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies.
Flood M; Narasimhan V; Waters P; Ramsay R; Michael M; Warrier S; Heriot A
Surgeon; 2021 Oct; 19(5):310-320. PubMed ID: 33023847
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective Study.
Fanget F; Kefleyesus A; Peron J; Bonnefoy I; Villeneuve L; Passot G; Rousset P; You B; Benzerdjeb N; Glehen O; Kepenekian V
Ann Surg Oncol; 2023 Jun; 30(6):3304-3315. PubMed ID: 36729351
[TBL] [Abstract][Full Text] [Related]
23. Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study.
Flood MP; Waters PS; Kelly ME; Shields C; Conneely J; Ramsay R; Michael M; Loveday B; Warrier SK; Mulsow J; Heriot AG
Surg Oncol; 2021 Jun; 37():101553. PubMed ID: 33839444
[TBL] [Abstract][Full Text] [Related]
24. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan.
Kitaguchi D; Park EJ; Baik SH; Sasaki S; Tsukada Y; Ito M
Int J Surg; 2024 Jan; 110(1):45-52. PubMed ID: 37800569
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
27. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
[TBL] [Abstract][Full Text] [Related]
28. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of perioperative efficacy and safety of cytoreductive surgery in the treatment of colorectal cancer peritoneal metastases].
Chen WW; Wang H; Li Y; Yuan ZX; Liu D; Wu ZJ; Deng WH; Luo R; Chen J; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):513-521. PubMed ID: 35754216
[No Abstract] [Full Text] [Related]
31. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
[TBL] [Abstract][Full Text] [Related]
32. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era.
Kelly ME; Murphy E; Keyes AM; Khan MF; Bolger JC; Grundy J; Conneely J; MacHale J; McCaffrey J; Cahill R; Moran B; Shields C; Mulsow J
Ir J Med Sci; 2021 Nov; 190(4):1373-1377. PubMed ID: 33420573
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
[TBL] [Abstract][Full Text] [Related]
35. Repeat cytoreductive surgery with HIPEC for colorectal peritoneal metastases: a systematic review.
Sarofim M; Wijayawardana R; Ahmadi N; Morris DL
World J Surg Oncol; 2024 Apr; 22(1):99. PubMed ID: 38627808
[TBL] [Abstract][Full Text] [Related]
36. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still beneficial in patients diagnosed with colorectal peritoneal metastasis who underwent palliative chemotherapy?
Cho HJ; Kim JW; Kim WR
Asian J Surg; 2024 Jan; 47(1):296-302. PubMed ID: 37648541
[TBL] [Abstract][Full Text] [Related]
37. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
38. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
[TBL] [Abstract][Full Text] [Related]
39. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study.
Dietz MV; Ziekman MJ; van Kooten JP; Brandt-Kerkhof ARM; van Meerten E; Verhoef C; Madsen EVE
Ann Surg Oncol; 2023 Apr; 30(4):2048-2056. PubMed ID: 36566258
[TBL] [Abstract][Full Text] [Related]
40. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]